Lina Khan, FTC chair (Graeme Jennings/Pool via AP Images)
Pile-on over PBMs continues with FTC comments and a new bipartisan Senate bill
More than 500 stakeholders sent comments to the FTC on whether the commission should look further into pharma middlemen, known as PBMs, with many of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.